All lobbying filings

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. filed a Q2 report for Regeneron Pharmaceuticals, Inc. on July 21, 2025.

Lobbying for Regeneron Pharmaceuticals, Inc.

As filed: REGENERON PHARMACEUTICALS, INC for REGENERON PHARMACEUTICALS, INC.

All filings by Regeneron Pharmaceuticals, Inc. · Everything Regeneron Pharmaceuticals, Inc. has reported

Filing · LD-2 quarterly report Q2 report

Reporting period

2nd Quarter 2025

Apr 1 - June 30 · Posted Jul 21, 2025

Expenses

$610,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

New York

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 5

Health Issues

Privacy legislation related to biopharmaceutical manufacturers; Food and Drug Administration issues related to biopharmaceutical manufacturers; National security issues related to biopharmaceutical manufacturers; Public-private contracts for innovation in the biopharmaceutical space; Issues related to defense spending; Issues related to step therapy; Issues related to health extenders; Issues related to Pandemic Preparedness and Response Program.

Medicare/Medicaid

Medicare and other drug pricing issues relating to biopharmaceutical manufacturers.

Patent issues relating to biopharmaceutical manufacturers; Intellectual property legislation related to biopharmaceutical manufacturers; Issues relating to WTO TRIPS waivers.

Trade (domestic/foreign)

Trade and tariff issues related to corporations.

Taxation/Internal Revenue Code

Tax and inflation issues related to corporations.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.